Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply
JAMA · 2023
DOI: 10.1001/jama.2023.9113 ↗Kurz gefasst
Leserbrief in der Zeitschrift JAMA, 2023. Verfasst von Gregory P Forlenza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Verapamil, Calcium Channel Blockers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center, University of Colorado Anschutz Medical Campus, Aurora.
- Division of Pediatric Cardiology, Indiana University School of Medicine, Indianapolis.
- Division of Pediatric Endocrinology, Stanford University, Palo Alto, California.
Zitieren
APA
Forlenza, G. P., Schamberger, M. S., & Buckingham, B. A. (2023). Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply. JAMA. https://doi.org/10.1001/jama.2023.9113
Vancouver
Forlenza GP, Schamberger MS, Buckingham BA. Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply. JAMA. 2023. doi:10.1001/jama.2023.9113
BibTeX
@article{Forlenza2023,
author = {Forlenza, Gregory P and Schamberger, Marcus S and Buckingham, Bruce A},
title = {Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes—Reply},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.9113}
}
EUVIMED